Update on non-melanoma skin cancer and the value of dermoscopy in its diagnosis and treatment monitoring

Expert Review of Anticancer Therapy

Volumn 13, Issue 5, 2013, Pages 541-558

  Lallas, Aimilios ^a   Argenziano, Giuseppe ^a   Zendri, Enrico ^a   Moscarella, Elvira ^a   Longo, Caterina ^a   Grenzi, Laura ^a   Pellacani, Giovanni ^a   Zalaudek, Iris ^a,b  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

actinic keratosis; basal cell carcinoma; Bowens' disease; dermoscopy; squamous cell carcinoma; treatment

Indexed keywords

AMINOLEVULINIC ACID; AMINOLEVULINIC ACID METHYL ESTER; DICLOFENAC; FLUOROURACIL; IMIQUIMOD; INGENOL MEBUTATE; RETINOID; SALICYLIC ACID;

ACTINIC KERATOSIS; BASAL CELL CARCINOMA; BOWEN DISEASE; BURNING SENSATION; CANCER PROGNOSIS; CLINICAL EXAMINATION; CRYOSURGERY; DERMATITIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; EROSION; ERYTHEMA; FOLLOW UP; GENE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; KERATINOCYTE SKIN CANCER; LOW LEVEL LASER THERAPY; MELANOMA; NON INVASIVE PROCEDURE; NON MELANOMA SKIN CANCER; PAIN; PATHOGENESIS; PATIENT MONITORING; PHOTODYNAMIC THERAPY; PHOTOSENSITIVITY; PREOPERATIVE EVALUATION; PRURITUS; PTCH1 GENE; REVIEW; SCAR FORMATION; SENSITIVITY AND SPECIFICITY; SKIN EDEMA; SKIN ULCER; SQUAMOUS CELL CARCINOMA; TP53 GENE; TREATMENT RESPONSE; WOUND INFECTION;

BOWEN'S DISEASE; CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; DERMOSCOPY; EARLY DETECTION OF CANCER; HUMANS; KERATOSIS, ACTINIC; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 84876850388     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.13.38     Document Type: Review

References (163)

1. Zalaudek I, Kreusch J, Giacomel J, Ferrara G, Catricalà C, Argenziano G. How to diagnose nonpigmented skin tumors: a review of vascular structures seen with dermoscopy: part II. Nonmelanocytic skin tumors. J. Am. Acad. Dermatol. 63(3), 377-386; quiz 387 (2010).
2. Gray DT, Suman VJ, Su WP, Clay RP, Harmsen WS, Roenigk RK. Trends in the population-based incidence of squamous cell carcinoma of the skin first diagnosed between 1984 and 1992. Arch. Dermatol. 133(6), 735-740 (1997).
3. Staples MP, Elwood M, Burton RC, Williams JL, Marks R, Giles GG. Non-melanoma skin cancer in Australia: the 2002 national survey and trends since 1985. Med. J. Aust. 184(1), 6-10 (2006).
4. Rubin AI, Chen EH, Ratner D. Basal-cell carcinoma. N. Engl. J. Med. 353(21), 2262-2269 (2005).
5. Alam M, Ratner D. Cutaneous squamouscell carcinoma. N. Engl. J. Med. 344(13), 975-983 (2001).
6. Chen JG, Fleischer AB Jr, Smith ED et al. Cost of nonmelanoma skin cancer treatment in the United States. Dermatol. Surg. 27(12), 1035-1038 (2001).
7. Argenziano G, Soyer HP, Chimenti S et al. Dermoscopy of pigmented skin lesions: results of a consensus meeting via the Internet. J. Am. Acad. Dermatol. 48(5), 679-693 (2003).
8. Kittler H, Pehamberger H, Wolff K, Binder M. Diagnostic accuracy of dermoscopy. Lancet Oncol. 3(3), 159-165 (2002).
9. Micantonio T, Fargnoli MC, Piccolo D, Peris K. Letter: changes in dermoscopic features in superficial basal cell carcinomas treated with imiquimod. Dermatol. Surg. 33(11), 1403-1405 (2007).
10. Diepgen TL, Mahler V. The epidemiology of skin cancer. Br. J. Dermatol. 146(Suppl. 61), 1-6 (2002).
11. Bradford PT. Skin cancer in skin of color. Dermatol. Nurs. 21(4), 170-177, 206; quiz
12. Madan V, Lear JT, Szeimies RM. Non-melanoma skin cancer. Lancet 375(9715), 673-685 (2010).
13. Zhang H, Ping XL, Lee PK et al. Role of PTCH and p53 genes in early-onset basal cell carcinoma. Am. J. Pathol. 158(2), 381-385 (2001).
14. Gailani MR, Bale SJ, Leffell DJ et al. Developmental defects in Gorlin syndrome related to a putative tumor suppressor gene on chromosome 9. Cell 69(1), 111-117 (1992).
15. Bale AE, Yu KP. The hedgehog pathway and basal cell carcinomas. Hum. Mol. Genet. 10(7), 757-762 (2001).
16. Menzies SW, Westerhoff K, Rabinovitz H, Kopf AW, McCarthy WH, Katz B. Surface microscopy of pigmented basal cell carcinoma. Arch. Dermatol. 136(8), 1012-1016 (2000).
17. Altamura D, Menzies SW, Argenziano G et al. Dermatoscopy of basal cell carcinoma: morphologic variability of global and local features and accuracy of diagnosis. J. Am. Acad. Dermatol. 62(1), 67-75 (2010).
18. Pan Y, Chamberlain AJ, Bailey M, Chong AH, Haskett M, Kelly JW. Dermatoscopy aids in the diagnosis of the solitary red scaly patch or plaque-features distinguishing superficial basal cell carcinoma, intraepidermal carcinoma, and psoriasis. J. Am. Acad. Dermatol. 59(2), 268-274 (2008).
19. Carducci M, Bozzetti M, Foscolo AM, Betti R. Margin detection using digital dermatoscopy improves the performance of traditional surgical excision of basal cell carcinomas of the head and neck. Dermatol. Surg. 37(2), 280-285 (2011).
20. Giacomel J, Zalaudek I. Dermoscopy of superficial basal cell carcinoma. Dermatol. Surg. 31(12), 1710-1713 (2005).
21. Zalaudek I, Ferrara G, Broganelli P et al. Dermoscopy patterns of fibroepithelioma of Pinkus. Arch. Dermatol. 142(10), 1318-1322 (2006).
22. Tiodorovic-Zivkovic D, Zalaudek I, Ferrara G et al. Clinical and dermatoscopic findings in Bazex-Dupré-Christol and Gorlin-Goltz syndromes. J. Am. Acad. Dermatol. 63(4), 722-724 (2010).
23. Bastiaens MT, Hoefnagel JJ, Bruijn JA, Westendorp RG, Vermeer BJ, Bouwes Bavinck JN. Differences in age, site distribution, and sex between nodular and superficial basal cell carcinoma indicate different types of tumors. J. Invest. Dermatol. 110(6), 880-884 (1998).
24. McCormack CJ, Kelly JW, Dorevitch AP. Differences in age and body site distribution of the histological subtypes of basal cell carcinoma. A possible indicator of differing causes. Arch. Dermatol. 133(5), 593-596 (1997).
25. Zalaudek I, Moscarella E, Longo C, de Pace B, Argenziano G. The 'signature' pattern of multiple basal cell carcinomas. Arch. Dermatol. 148(9), 1106 (2012).
26. Telfer NR, Colver GB, Morton CA; British Association of Dermatologists. Guidelines for the management of basal cell carcinoma. Br. J. Dermatol. 159(1), 35-48 (2008).
27. Morton CA, Szeimies RM, Sidoroff A, Braathen LR. European guidelines for topical photodynamic therapy part 1: treatment delivery and current indications -actinic keratoses, Bowen's disease, basal cell carcinoma. J. Eur. Acad. Dermatol. Venereol. doi:10.1111/jdv.12031 (2012) (Epub ahead of print).
28. Peris K, Ferrari A, Fargnoli MC, Piccolo D, Chimenti S. Dermoscopic monitoring of tazarotene treatment of superficial basal cell carcinoma. Dermatol. Surg. 31(2), 217-220 (2005).
29. Lacarrubba F, D'Amico V, Nasca MR, Dinotta F, Micali G. Use of dermatoscopy and videodermatoscopy in therapeutic follow-up: a review. Int. J. Dermatol. 49(8), 866-873 (2010).
30. Quatresooz P, Piérard-Franchimont C, Paquet P, Hubert P, Delvenne P, Piérard GE. Crossroads between actinic keratosis and squamous cell carcinoma, and novel pharmacological issues. Eur. J. Dermatol. 18(1), 6-10 (2008).
31. Memon AA, Tomenson JA, Bothwell J, Friedmann PS. Prevalence of solar damage and actinic keratosis in a Merseyside population. Br. J. Dermatol. 142(6), 1154-1159 (2000).
32. Frost C, Williams G, Green A. High incidence and regression rates of solar keratoses in a queensland community. J. Invest. Dermatol. 115(2), 273-277 (2000).
33. Brash DE, Ziegler A, Jonason AS, Simon JA, Kunala S, Leffell DJ. Sunlight and sunburn in human skin cancer: p53, apoptosis, and tumor promotion. J. Investig. Dermatol. Symp. Proc. 1(2), 136-142 (1996).
34. Ulrich C, Christophers E, Sterry W, Meyer T, Stockfleth E. [Skin diseases in organ transplant patients]. Hautarzt 53(8), 524-533 (2002).
35. Rehman I, Quinn AG, Healy E, Rees JL. High frequency of loss of heterozygosity in actinic keratoses, a usually benign disease. Lancet 344(8925), 788-789 (1994).
36. Park WS, Lee HK, Lee JY, Yoo NJ, Kim CS, Kim SH. p53 mutations in solar keratoses. Hum. Pathol. 27(11), 1180-1184 (1996).
37. Smoller BR. Squamous cell carcinoma: from precursor lesions to high-risk variants. Mod. Pathol. 19(Suppl. 2), S88-S92 (2006).
38. Cockerell CJ. Histopathology of incipient intraepidermal squamous cell carcinoma ('actinic keratosis'). J. Am. Acad. Dermatol. 42(1 Pt 2), 11-17 (2000).
39. Braakhuis BJ, Tabor MP, Kummer JA, Leemans CR, Brakenhoff RH. A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications. Cancer Res. 63(8), 1727-1730 (2003).
40. Röwert-Huber J, Patel MJ, Forschner T et al. Actinic keratosis is an early in situ squamous cell carcinoma: a proposal for reclassification. Br. J. Dermatol. 156(Suppl. 3), 8-12 (2007).
41. Zalaudek I, Giacomel J, Argenziano G et al. Dermoscopy of facial nonpigmented actinic keratosis. Br. J. Dermatol. 155(5), 951-956 (2006).
42. Zalaudek I, Giacomel J, Schmid K et al. Dermatoscopy of facial actinic keratosis, intraepidermal carcinoma, and invasive squamous cell carcinoma: a progression model. J. Am. Acad. Dermatol. 66(4), 589-597 (2012).
43. Huerta-Brogeras M, Olmos O, Borbujo J et al. Validation of dermoscopy as a real-time noninvasive diagnostic imaging technique for actinic keratosis. Arch. Dermatol. 148(10), 1159-1164 (2012).
44. Green A, Battistutta D. Incidence and determinants of skin cancer in a high-risk Australian population. Int. J. Cancer 46(3), 356-361 (1990).
45. Glogau RG. The risk of progression to invasive disease. J. Am. Acad. Dermatol. 42(1 Pt 2), 23-24 (2000).
46. Stockfleth E, Ferrandiz C, Grob JJ, Leigh I, Pehamberger H, Kerl H; European Skin Academy. Development of a treatment algorithm for actinic keratoses: a European Consensus. Eur. J. Dermatol. 18(6), 651-659 (2008).
47. de Berker D, McGregor JM, Hughes BR; British Association of Dermatologists Therapy Guidelines and Audit Subcommittee. Guidelines for the Management of Actinic Keratoses. Br. J. Dermatol. 156(2), 222-230 (2007).
48. Stockfleth E, Kerl H; Guideline Subcommittee of the European Dermatology Forum. Guidelines for the Management of Actinic Keratoses. Eur. J. Dermatol. 16(6), 599-606 (2006).
49. Kaçar N, Sanli B, Zalaudek I, Yildiz N, Ergin S. Dermatoscopy for monitoring treatment of actinic keratosis with imiquimod. Clin. Exp. Dermatol. 37(5), 567-569 (2012).
50. Lee MM, Wick MM. Bowen's disease. CA. Cancer J. Clin. 40(4), 237-242 (1990).
51. Cassarino DS, Derienzo DP, Barr RJ. Cutaneous squamous cell carcinoma: a comprehensive clinicopathologic classification. Part one. J. Cutan. Pathol. 33(3), 191-206 (2006).
52. Chute CG, Chuang TY, Bergstralh EJ, Su WP. The subsequent risk of internal cancer with Bowen's disease. A population-based study. JAMA 266(6), 816-819 (1991).
53. Kossard S, Rosen R. Cutaneous Bowen's disease. An analysis of 1001 cases according to age, sex, and site. J. Am. Acad. Dermatol. 27(3), 406-410 (1992).
54. Shannon RL, Strayer DS. Arsenic-induced skin toxicity. Hum. Toxicol. 8(2), 99-104 (1989).
55. Shim WH, Park HJ, Kim HS et al. Bowenoid Papulosis of the Vulva and Subsequent Periungual Bowen's Disease Induced by the Same Mucosal HPVs. Ann. Dermatol. 23(4), 493-496 (2011).
56. Drake AL, Walling HW. Variations in presentation of squamous cell carcinoma in situ (Bowen's disease) in immunocompromised patients. J. Am. Acad. Dermatol. 59(1), 68-71 (2008).
57. Cox NH, Eedy DJ, Morton CA; Therapy Guidelines and Audit Subcommittee, British Association of Dermatologists. Guidelines for management of Bowen's disease: 2006 update. Br. J. Dermatol. 156(1), 11-21 (2007).
58. Zalaudek I, Argenziano G, Leinweber B et al. Dermoscopy of Bowen's disease. Br. J. Dermatol. 150(6), 1112-1116 (2004).
59. Cameron A, Rosendahl C, Tschandl P, Riedl E, Kittler H. Dermatoscopy of pigmented Bowen's disease. J. Am. Acad. Dermatol. 62(4), 597-604 (2010).
60. Hu SC, Chiu HH, Chen GS, Ke CL, Cheng ST. Dermoscopy as a diagnostic and follow-up tool for pigmented Bowen's disease on acral region. Dermatol. Surg. 34(9), 1248-1253; discussion 1253 (2008).
61. Kao GF. Carcinoma arising in Bowen's disease. Arch. Dermatol. 122(10), 1124-1126 (1986).
62. Johnson TM, Rowe DE, Nelson BR, Swanson NA. Squamous cell carcinoma of the skin (excluding lip and oral mucosa). J. Am. Acad. Dermatol. 26(3 Pt 2), 467-484 (1992).
63. de Gruijl FR, Rebel H. Early events in UV carcinogenesis-DNA damage, target cells and mutant p53 foci. Photochem. Photobiol. 84(2), 382-387 (2008).
64. Fears TR, Scotto J. Estimating increases in skin cancer morbidity due to increases in ultraviolet radiation exposure. Cancer Invest. 1(2), 119-126 (1983).
65. Wehner MR, Shive ML, Chren MM, Han J, Qureshi AA, Linos E. Indoor tanning and non-melanoma skin cancer: systematic review and meta-analysis. BMJ 345, e5909 (2012).
66. Jensen P, Hansen S, Møller B et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J. Am. Acad. Dermatol. 40(2 Pt 1), 177-186 (1999).
67. Kwa RE, Campana K, Moy RL. Biology of cutaneous squamous cell carcinoma. J. Am. Acad. Dermatol. 26(1), 1-26 (1992).
68. Epstein E, Epstein NN, Bragg K, Linden G. Metastases from squamous cell carcinomas of the skin. Arch. Dermatol. 97(3), 245-251 (1968).
69. Frankel DH, Hanusa BH, Zitelli JA. New primary nonmelanoma skin cancer in patients with a history of squamous cell carcinoma of the skin. Implications and recommendations for follow-up. J. Am. Acad. Dermatol. 26(5 Pt 1), 720-726 (1992).
70. Cowen EW, Billingsley EM. Awareness of skin cancer by kidney transplant patients. J. Am. Acad. Dermatol. 40(5 Pt 1), 697-701 (1999).
71. Cassarino DS, Derienzo DP, Barr RJ. Cutaneous squamous cell carcinoma: a comprehensive clinicopathologic classification -part two. J. Cutan. Pathol. 33(4), 261-279 (2006).
72. Rosendahl C, Cameron A, Argenziano G, Zalaudek I, Tschandl P, Kittler H. Dermoscopy of squamous cell carcinoma and keratoacanthoma. Arch. Dermatol. 148(12), 1386-1392 (2012).
73. Zalaudek I, Kreusch J, Giacomel J, Ferrara G, Catricalà C, Argenziano G. How to diagnose nonpigmented skin tumors: a review of vascular structures seen with dermoscopy: part I. Melanocytic skin tumors. J. Am. Acad. Dermatol. 63(3), 361-74; quiz 375 (2010).
74. Clark JR, Rumcheva P, Veness MJ. Analysis and comparison of the 7th edition American Joint Committee on Cancer (AJCC) nodal staging system for metastatic cutaneous squamous cell carcinoma of the head and neck. Ann. Surg. Oncol. 19(13), 4252-4258 (2012).
75. Jambusaria-Pahlajani A, Kanetsky PA, Karia PS et al. Evaluation of AJCC tumor staging for cutaneous squamous cell carcinoma and a proposed alternative tumor staging system. JAMA Dermatol. 1-9, doi:10.1001/jamadermatol.2013.2456 (2013) (Epub ahead of print).
76. Miller SJ. Staging cutaneous squamous cell carcinoma. JAMA Dermatol. 1-3, doi:10.1001/jamadermatol.2013.2385. (2013) (Epub ahead of print).
77. Rowe DE, Carroll RJ, Day CL Jr. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection. J. Am. Acad. Dermatol. 26(6), 976-990 (1992).
78. Ross AS, Schmults CD. Sentinel lymph node biopsy in cutaneous squamous cell carcinoma: a systematic review of the English literature. Dermatol. Surg. 32(11), 1309-1321 (2006).
79. Brantsch KD, Meisner C, Schönfisch B et al. Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study. Lancet Oncol. 9(8), 713-720 (2008).
80. Motley R, Kersey P, Lawrence C; British Association of Dermatologists; British Association of Plastic Surgeons. Multiprofessional guidelines for the management of the patient with primary cutaneous squamous cell carcinoma. Br. J. Plast. Surg. 56(2), 85-91 (2003).
81. Rapini RP. Comparison of methods for checking surgical margins. J. Am. Acad. Dermatol. 23(2 Pt 1), 288-294 (1990).
82. Kuflik EG, Gage AA. The five-year cure rate achieved by cryosurgery for skin cancer. J. Am. Acad. Dermatol. 24(6 Pt 1), 1002-1004 (1991).
83. Tiodorovic-Zivkovic D, Zalaudek I, Longo C, De Pace B, Albertini G, Argenziano G. Successful treatment of two invasive squamous cell carcinomas with topical 5% imiquimod cream in elderly patients. Eur. J. Dermatol. 22(4), 579-580 (2012).
84. Fargnoli MC, Kostaki D, Piccioni A, Micantonio T, Peris K. Dermoscopy in the diagnosis and management of non-melanoma skin cancers. Eur. J. Dermatol. 22(4), 456-463 (2012).
85. Micantonio T, Gulia A, Altobelli E et al. Vascular patterns in basal cell carcinoma. J. Eur. Acad. Dermatol. Venereol. 25(3), 358-361 (2011).
86. Scalvenzi M, Lembo S, Francia MG, Balato A. Dermoscopic patterns of superficial basal cell carcinoma. Int. J. Dermatol. 47(10), 1015-1018 (2008).
87. Marghoob AA, Cowell L, Kopf AW, Scope A. Observation of chrysalis structures with polarized dermoscopy. Arch. Dermatol. 145(5), 618 (2009).
88. Walker P, Hill D. Surgical treatment of basal cell carcinomas using standard postoperative histological assessment. Australas. J. Dermatol. 47(1), 1-12 (2006).
89. Marchac D, Papadopoulos O, Duport G. Curative and aesthetic results of surgical treatment of 138 basal-cell carcinomas. J. Dermatol. Surg. Oncol. 8(5), 379-387 (1982).
90. Griffiths RW, Suvarna SK, Stone J. Do basal cell carcinomas recur after complete conventional surgical excision? Br. J. Plast. Surg. 58(6), 795-805 (2005).
91. Wennberg AM, Larkö O, Stenquist B. Fiveyear results of Mohs' micrographic surgery for aggressive facial basal cell carcinoma in Sweden. Acta Derm. Venereol. 79(5), 370-372 (1999).
92. Leibovitch I, Huilgol SC, Selva D, Richards S, Paver R. Basal cell carcinoma treated with Mohs surgery in Australia II. Outcome at 5-year follow-up. J. Am. Acad. Dermatol. 53(3), 452-457 (2005).
93. Smeets NW, Kuijpers DI, Nelemans P et al. Mohs' micrographic surgery for treatment of basal cell carcinoma of the face-results of a retrospective study and review of the literature. Br. J. Dermatol. 151(1), 141-147 (2004).
94. Kimyai-Asadi A, Goldberg LH, Peterson SR, Silapint S, Jih MH. The incidence of major complications from Mohs micrographic surgery performed in office-based and hospital-based settings. J. Am. Acad. Dermatol. 53(4), 628-634 (2005).
95. Boztepe G, Hohenleutner S, Landthaler M, Hohenleutner U. Munich method of micrographic surgery for basal cell carcinomas: 5-year recurrence rates with life-table analysis. Acta Derm. Venereol. 84(3), 218-222 (2004).
96. Smeets NW, Krekels GA, Ostertag JU et al. Surgical excision vs Mohs' micrographic surgery for basal-cell carcinoma of the face: randomised controlled trial. Lancet 364(9447), 1766-1772 (2004).
97. Barlow JO, Zalla MJ, Kyle A, DiCaudo DJ, Lim KK, Yiannias JA. Treatment of basal cell carcinoma with curettage alone. J. Am. Acad. Dermatol. 54(6), 1039-1045 (2006).
98. Silverman MK, Kopf AW, Grin CM, Bart RS, Levenstein MJ. Recurrence rates of treated basal cell carcinomas. Part 2: curettage-electrodesiccation. J. Dermatol. Surg. Oncol. 17(9), 720-726 (1991).
99. Bernardeau K, Derancourt C, Cambie M et al. [Cryosurgery of basal cell carcinoma: a study of 358 patients]. Ann. Dermatol. Venereol. 127(2), 175-179 (2000).
100. Kuflik EG. Cryosurgery for skin cancer: 30-year experience and cure rates. Dermatol. Surg. 30(2 Pt 2), 297-300 (2004).
101. Wang I, Bendsoe N, Klinteberg CA et al. Photodynamic therapy vs. cryosurgery of basal cell carcinomas: results of a Phase III clinical trial. Br. J. Dermatol. 144(4), 832-840 (2001).
102. Childers BJ, Goldwyn RM, Ramos D, Chaffey J, Harris Jr. Long-term results of irradiation for basal cell carcinoma of the skin of the nose. Plast. Reconstr. Surg. 93(6), 1169-1173 (1994).
103. Zagrodnik B, Kempf W, Seifert B et al. Superficial radiotherapy for patients with basal cell carcinoma: recurrence rates, histologic subtypes, and expression of p53 and Bcl-2. Cancer 98(12), 2708-2714 (2003).
104. Petit JY, Avril MF, Margulis A et al. Evaluation of cosmetic results of a randomized trial comparing surgery and radiotherapy in the treatment of basal cell carcinoma of the face. Plast. Reconstr. Surg. 105(7), 2544-2551 (2000).
105. Geisse J, Caro I, Lindholm J, Golitz L, Stampone P, Owens M. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two Phase III, randomized, vehicle-controlled studies. J. Am. Acad. Dermatol. 50(5), 722-733 (2004).
106. Schulze HJ, Cribier B, Requena L et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled Phase III study in Europe. Br. J. Dermatol. 152(5), 939-947 (2005).
107. Eigentler TK, Kamin A, Weide BM et al. A Phase III, randomized, open label study to evaluate the safety and efficacy of imiquimod 5% cream applied thrice weekly for 8 and 12 weeks in the treatment of low-risk nodular basal cell carcinoma. J. Am. Acad. Dermatol. 57(4), 616-621 (2007).
108. Soler AM, Warloe T, Berner A, Giercksky KE. A follow-up study of recurrence and cosmesis in completely responding superficial and nodular basal cell carcinomas treated with methyl 5-amino-laevulinate-based photodynamic therapy alone and with prior curettage. Br. J. Dermatol. 145(3), 467-471 (2001).
109. Rhodes LE, de Rie MA, Leifsdottir R et al. Five-year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma. Arch. Dermatol. 143(9), 1131-1136 (2007).
110. Peris K, Micantonio T, Piccolo D, Fargnoli MC. Dermoscopic features of actinic keratosis. J. Dtsch. Dermatol. Ges. 5(11), 970-976 (2007).
111. Cuellar F, Vilalta A, Puig S, Palou J, Salerni G, Malvehy J. New dermoscopic pattern in actinic keratosis and related conditions. Arch. Dermatol. 145(6), 732 (2009).
112. Emmett AJ, Broadbent GD. Shave excision of superficial solar skin lesions. Plast. Reconstr. Surg. 80(1), 47-54 (1987).
113. Dinehart SM. The treatment of actinic keratoses. J. Am. Acad. Dermatol. 42(1 Pt 2), 25-28 (2000).
114. Szeimies RM, Radakovic S, Calzavara-Pinton PG et al. A prospective, randomized study comparing photodynamic therapy with Metvix® to cryotherapy in actinic keratoses. J. Eur. Acad. Dermatol. Venereol. 14(2), 235 (2000).
115. Graham GF. Cryosurgery in the management of cutaneous malignancies. Clin. Dermatol. 19(3), 321-327 (2001).
116. Chiarello SE. Cryopeeling (extensive cryosurgery) for treatment of actinic keratoses: an update and comparison. Dermatol. Surg. 26(8), 728-732 (2000).
117. Krawtchenko N, Roewert-Huber J, Ulrich M, Mann I, Sterry W, Stockfleth E. A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up. Br. J. Dermatol. 157(Suppl. 2), 34-40 (2007).
118. Wollina U, Konrad H, Karamfilov T. Treatment of common warts and actinic keratoses by Er:YAG laser. J. Cutan. Laser Ther. 3(2), 63-66 (2001).
119. Lawrence N, Cox SE, Cockerell CJ, Freeman RG, Cruz PD Jr. A comparison of the efficacy and safety of Jessner's solution and 35% trichloroacetic acid vs 5% fluorouracil in the treatment of widespread facial actinic keratoses. Arch. Dermatol. 131(2), 176-181 (1995).
120. Stone PA. The use of modified phenol for chemical face peeling. Clin. Plast. Surg. 25(1), 21-44 (1998).
121. Sorg O, Tran C, Saurat JH. Cutaneous vitamins A and E in the context of ultraviolet-or chemically-induced oxidative stress. Skin Pharmacol. Appl. Skin Physiol. 14(6), 363-372 (2001).
122. Szeimies RM, Karrer S, Radakovic-Fijan S et al. Photodynamic therapy using topical methyl 5-aminolevulinate compared with cryotherapy for actinic keratosis: a prospective, randomized study. J. Am. Acad. Dermatol. 47(2), 258-262 (2002).
123. Morton CA, Brown SB, Collins S et al. Guidelines for topical photodynamic therapy: report of a workshop of the British Photodermatology Group. Br. J. Dermatol. 146(4), 552-567 (2002).
124. Pariser DM, Lowe NJ, Stewart DM et al. Photodynamic therapy with topical methyl aminolevulinate for actinic keratosis: results of a prospective randomized multicenter trial. J. Am. Acad. Dermatol. 48(2), 227-232 (2003).
125. Freeman M, Vinciullo C, Francis D et al. A comparison of photodynamic therapy using topical methyl aminolevulinate (Metvix) with single cycle cryotherapy in patients with actinic keratosis: a prospective, randomized study. J. Dermatolog. Treat. 14(2), 99-106 (2003).
126. Gupta AK. The management of actinic keratoses in the United States with topical fluorouracil: a pharmacoeconomic evaluation. Cutis. 70(Suppl. 2), 30-36 (2002).
127. Rivers JK, Arlette J, Shear N, Guenther L, Carey W, Poulin Y. Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gel. Br. J. Dermatol. 146(1), 94-100 (2002).
128. Rivers JK, McLean DI. An open study to assess the efficacy and safety of topical 3% diclofenac in a 2.5% hyaluronic acid gel for the treatment of actinic keratoses. Arch. Dermatol. 133(10), 1239-1242 (1997).
129. Wolf JE Jr, Taylor JR, Tschen E, Kang S. Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses. Int. J. Dermatol. 40(11), 709-713 (2001).
130. Campanelli A, Naldi L. A retrospective study of the effect of long-term topical application of retinaldehyde (0.05%) on the development of actinic keratosis. Dermatology (Basel) 205(2), 146-152 (2002).
131. Humphreys TR, Werth V, Dzubow L, Kligman A. Treatment of photodamaged skin with trichloroacetic acid and topical tretinoin. J. Am. Acad. Dermatol. 34(4), 638-644 (1996).
132. Bernard P, Dupuy A, Brun P et al. Treatment of superficial basal cell carcinomas and multiple actinic keratoses by French dermatologists: a prospective medical cost analysis. Ann. Dermatol. Venereol. 134(6), 527-533 (2007).
133. Stockfleth E, Christophers E, Benninghoff B, Sterry W. Low incidence of new actinic keratoses after topical 5% imiquimod cream treatment: a long-term follow-up study. Arch. Dermatol. 140(12), 1542 (2004).
134. Lebwohl M, Dinehart S, Whiting D et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from two Phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J. Am. Acad. Dermatol. 50(5), 714-721 (2004).
135. Swanson N, Abramovits W, Berman B, Kulp J, Rigel DS, Levy S. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles. J. Am. Acad. Dermatol. 62(4), 582-590 (2010).
136. Hanke CW, Beer KR, Stockfleth E, Wu J, Rosen T, Levy S. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 3-week cycles. J. Am. Acad. Dermatol. 62(4), 573-581 (2010).
137. Hanke CW, Swanson N, Bruce S, Berman B, Kulp J, Levy S. Complete clearance is sustained for at least 12 months after treatment of actinic keratoses of the face or balding scalp via daily dosing with imiquimod 3.75% or 2.5% cream. J. Drugs Dermatol. 10(2), 165-170 (2011).
138. Anderson L, Schmieder GJ, Werschler WP et al. Randomized, double-blind, doubledummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis. J. Am. Acad. Dermatol. 60(6), 934-943 (2009).
139. Siller G, Gebauer K, Welburn P, Katsamas J, Ogbourne SM. PEP005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis: results of a randomized, double-blind, vehicle-controlled, multicentre, Phase IIa study. Australas. J. Dermatol. 50(1), 16-22 (2009).
140. Lebwohl M, Swanson N, Anderson LL, Melgaard A, Xu Z, Berman B. Ingenol mebutate gel for actinic keratosis. N. Engl. J. Med. 366(11), 1010-1019 (2012).
141. Stockfleth E, Kerl H, Zwingers T, Willers C. Low-dose 5-fluorouracil in combination with salicylic acid as a new lesion-directed option to treat topically actinic keratoses: histological and clinical study results. Br. J. Dermatol. 165(5), 1101-1108 (2011).
142. Stockfleth E, Zwingers T, Willers C. Recurrence rates and patient assessed outcomes of 0.5% 5-fluorouracil in combination with salicylic acid treating actinic keratoses. Eur. J. Dermatol. 22(3), 370-374 (2012).
143. Thestrup-Pedersen K, Ravnborg L, Reymann F. Morbus Bowen. A description of the disease in 617 patients. Acta Derm. Venereol. 68(3), 236-239 (1988).
144. Cleary RK, Schaldenbrand JD, Fowler JJ, Schuler JM, Lampman RM. Treatment options for perianal Bowen's disease: survery of American Society of Colon and Rectal Surgeons Members. Am. Surg. 66(7), 686-688 (2000).
145. Leibovitch I, Huilgol SC, Selva D, Richards S, Paver R. Cutaneous squamous carcinoma in situ (Bowen's disease): treatment with Mohs micrographic surgery. J. Am. Acad. Dermatol. 52(6), 997-1002 (2005).
146. Tantikun N. Treatment of Bowen's disease of the digit with carbon dioxide laser. J. Am. Acad. Dermatol. 43(6), 1080-1083 (2000).
147. Dave R, Monk B, Mahaffey P. Treatment of Bowen's disease with carbon dioxide laser. Lasers Surg. Med. 32(5), 335 (2003).
148. Ahmed I, Berth-Jones J, Charles-Holmes S, O'Callaghan CJ, Ilchyshyn A. Comparison of cryotherapy with curettage in the treatment of Bowen's disease: a prospective study. Br. J. Dermatol. 143(4), 759-766 (2000).
149. Holt PJ. Cryotherapy for skin cancer: results over a 5-year period using liquid nitrogen spray cryosurgery. Br. J. Dermatol. 119(2), 231-240 (1988).
150. Morton CA, Whitehurst C, Moseley H, McColl JH, Moore JV, Mackie RM. Comparison of photodynamic therapy with cryotherapy in the treatment of Bowen's disease. Br. J. Dermatol. 135(5), 766-771 (1996).
151. Blank AA, Schnyder UW. Soft-X-ray therapy in Bowen's disease and erythroplasia of Queyrat. Dermatologica 171(2), 89-94 (1985).
152. Dupree MT, Kiteley RA, Weismantle K, Panos R, Johnstone PA. Radiation therapy for Bowen's disease: lessons for lesions of the lower extremity. J. Am. Acad. Dermatol. 45(3), 401-404 (2001).
153. Chung YL, Lee JD, Bang D, Lee JB, Park KB, Lee MG. Treatment of Bowen's disease with a specially designed radioactive skin patch. Eur. J. Nucl. Med. 27(7), 842-846 (2000).
154. Patel GK, Goodwin R, Chawla M et al. Imiquimod 5% cream monotherapy for cutaneous squamous cell carcinoma in situ (Bowen's disease): a randomized, doubleblind, placebo-controlled trial. J. Am. Acad. Dermatol. 54(6), 1025-1032 (2006).
155. Prinz BM, Hafner J, Dummer R, Burg G, Bruswanger U, Kempf W. Treatment of Bowen's disease with imiquimod 5% cream in transplant recipients. Transplantation 77(5), 790-791 (2004).
156. Smith KJ, Germain M, Skelton H. Bowen's disease (squamous cell carcinoma in situ) in immunosuppressed patients treated with imiquimod 5% cream and a cox inhibitor, sulindac: potential applications for this combination of immunotherapy. Dermatol. Surg. 27(2), 143-146 (2001).
157. Welch ML, Grabski WJ, McCollough ML et al. 5-fluorouracil iontophoretic therapy for Bowen's disease. J. Am. Acad. Dermatol. 36(6 Pt 1), 956-958 (1997).
158. Salim A, Leman JA, McColl JH, Chapman R, Morton CA. Randomized comparison of photodynamic therapy with topical 5-fluorouracil in Bowen's disease. Br. J. Dermatol. 148(3), 539-543 (2003).
159. Bargman H, Hochman J. Topical treatment of Bowen's disease with 5-fluorouracil. J. Cutan. Med. Surg. 7(2), 101-105 (2003).
160. Varma S, Wilson H, Kurwa HA et al. Bowen's disease, solar keratoses and superficial basal cell carcinomas treated by photodynamic therapy using a large-field incoherent light source. Br. J. Dermatol. 144(3), 567-574 (2001).
161. Morton C, Horn M, Leman J et al. Comparison of topical methyl aminolevulinate photodynamic therapy with cryotherapy or fluorouracil for treatment of squamous cell carcinoma in situ: results of a multicenter randomized trial. Arch. Dermatol. 142(6), 729-735 (2006).
162. Perrett CM, McGregor JM, Warwick J et al. Treatment of post-transplant premalignant skin disease: a randomized intrapatient comparative study of 5-fluorouracil cream and topical photodynamic therapy. Br. J. Dermatol. 156(2), 320-328 (2007).
163. de Haas ER, Sterenborg HJ, Neumann HA, Robinson DJ. Response of Bowen disease to ALA-PDT using a single and a 2-fold illumination scheme. Arch. Dermatol. 143(2), 264-265 (2007).